MeSH term
Frequency | Condition_Probility | Adult | 44 | 0.0 |
Aged | 24 | 0.0 |
Female | 46 | 0.0 |
Humans | 148 | 0.0 |
Male | 52 | 0.0 |
Middle Aged | 35 | 0.0 |
Adolescent | 21 | 0.0 |
Antibodies, Antineutrophil Cytoplasmic/blood/*immunology | 3 | 60.0 |
Antibodies, Monoclonal | 4 | 0.0 |
Blood Proteins/immunology | 4 | 21.0 |
Cohort Studies | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 20 | 0.0 |
Lactoferrin/immunology | 6 | 50.0 |
*Membrane Proteins | 111 | 10.0 |
Peroxidase/immunology | 6 | 16.0 |
Serine Endopeptidases/immunology | 5 | 22.0 |
Blood Proteins/*immunology | 13 | 40.0 |
Infant, Newborn | 3 | 0.0 |
Neutrophils/*immunology | 11 | 6.0 |
Blood Proteins/*metabolism | 14 | 7.0 |
Child | 14 | 0.0 |
Child, Preschool | 8 | 0.0 |
Defensins/*metabolism | 2 | 100.0 |
Infant | 5 | 0.0 |
Reference Values | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 79 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 52 | 0.0 |
*Acute-Phase Proteins | 15 | 7.0 |
Amino Acid Sequence | 21 | 0.0 |
Animals | 53 | 0.0 |
Base Sequence | 8 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Lipopolysaccharides/pharmacology | 7 | 0.0 |
*Membrane Glycoproteins | 22 | 2.0 |
Molecular Sequence Data | 28 | 0.0 |
Phylogeny | 2 | 0.0 |
Cattle | 4 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Blood Proteins/*pharmacology | 8 | 20.0 |
Cell Membrane Permeability/drug effects | 2 | 3.0 |
Neutrophils/immunology | 3 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
Cell Line | 10 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Anti-Bacterial Agents/*therapeutic use | 5 | 10.0 |
Blood Bactericidal Activity/drug effects | 2 | 20.0 |
Clinical Trials, Phase I | 2 | 3.0 |
Clinical Trials, Phase II | 2 | 3.0 |
Gram-Negative Bacterial Infections/*drug therapy | 2 | 100.0 |
Recombinant Proteins/therapeutic use | 6 | 1.0 |
Cells, Cultured | 6 | 0.0 |
Comparative Study | 15 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Mice | 13 | 0.0 |
Blood Proteins/pharmacology | 3 | 6.0 |
Culture Media | 3 | 0.0 |
Neutrophils/*metabolism | 2 | 1.0 |
Rabbits | 8 | 0.0 |
Genetic Heterogeneity | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Bipolar Disorder/*genetics | 2 | 1.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Genotype | 3 | 0.0 |
Receptors, Serotonin/*genetics | 2 | 2.0 |
Blood Bactericidal Activity | 26 | 27.0 |
Escherichia coli/immunology | 6 | 8.0 |
Antibodies, Antineutrophil Cytoplasmic/*blood/immunology | 2 | 50.0 |
Fluorescent Antibody Technique, Indirect | 8 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Double-Blind Method | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Antibodies, Antineutrophil Cytoplasmic/*immunology | 8 | 28.0 |
Antibody Specificity | 3 | 0.0 |
Autoantigens/*immunology | 4 | 2.0 |
Neutrophils/metabolism | 2 | 1.0 |
Vasculitis/immunology | 2 | 11.0 |
*Glycoproteins | 3 | 0.0 |
*Phospholipid Transfer Proteins | 2 | 1.0 |
Colitis, Ulcerative/*immunology | 3 | 8.0 |
Vasculitis/*immunology | 2 | 10.0 |
Aged, 80 and over | 9 | 0.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Phospholipases A/metabolism | 3 | 5.0 |
Prognosis | 2 | 0.0 |
Prospective Studies | 9 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 4 | 0.0 |
Blood Proteins/physiology | 2 | 11.0 |
Electrostatics | 2 | 1.0 |
Models, Molecular | 9 | 0.0 |
Permeability/drug effects | 2 | 8.0 |
Phospholipids/metabolism | 2 | 1.0 |
Blood Proteins/genetics/*metabolism | 2 | 11.0 |
Protein Structure, Tertiary | 7 | 0.0 |
Structure-Activity Relationship | 11 | 0.0 |
Transfection | 4 | 0.0 |
Endotoxins | 2 | 9.0 |
Membrane Proteins/*therapeutic use | 2 | 28.0 |
United States | 3 | 0.0 |
Anti-Bacterial Agents/*pharmacology | 2 | 1.0 |
*Blood Bactericidal Activity | 16 | 34.0 |
Recombinant Proteins/pharmacology | 5 | 0.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 3 | 0.0 |
Chemiluminescent Measurements | 5 | 3.0 |
Fluorescein-5-isothiocyanate | 4 | 2.0 |
Lipopolysaccharides/*metabolism | 9 | 7.0 |
Binding Sites | 8 | 0.0 |
Cystic Fibrosis/*immunology/microbiology/physiopathology | 2 | 100.0 |
Neutrophil Activation | 4 | 8.0 |
Pseudomonas aeruginosa/immunology | 2 | 20.0 |
Cell Division/drug effects | 2 | 0.0 |
Crystallography, X-Ray | 4 | 0.0 |
Protein Structure, Secondary | 5 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
Escherichia coli/*drug effects/growth & development/metabolism | 2 | 100.0 |
*Escherichia coli Proteins | 2 | 0.0 |
Fermentation | 2 | 5.0 |
Autoantibodies/*blood | 4 | 1.0 |
Seroepidemiologic Studies | 2 | 1.0 |
Binding, Competitive | 8 | 0.0 |
CHO Cells | 4 | 0.0 |
Hamsters | 4 | 0.0 |
Blood Proteins/*chemistry/genetics | 2 | 50.0 |
Restriction Mapping | 2 | 0.0 |
English Abstract | 3 | 0.0 |
Sepsis/*drug therapy | 2 | 16.0 |
Blood Bactericidal Activity/*immunology | 6 | 75.0 |
Defensins | 3 | 21.0 |
Blood Proteins/*analysis | 5 | 3.0 |
Colon/*metabolism/pathology | 2 | 16.0 |
Intestinal Mucosa/*metabolism/pathology | 2 | 12.0 |
Escherichia coli | 4 | 0.0 |
Rats | 12 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Epitope Mapping | 2 | 0.0 |
Antibodies, Antineutrophil Cytoplasmic/*blood | 3 | 12.0 |
Biological Markers | 2 | 0.0 |
Blotting, Western | 9 | 0.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Mutation | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Disulfides/metabolism | 2 | 5.0 |
Fluorescent Dyes | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Monocytes/metabolism | 2 | 0.0 |
Neutralization Tests | 2 | 0.0 |
Respiratory Burst | 2 | 3.0 |
Protein Binding | 7 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
Antigens, CD/blood | 2 | 0.0 |
Antigens, CD14/*blood | 2 | 6.0 |
Carrier Proteins/*blood | 5 | 2.0 |
Lipopolysaccharides/metabolism | 7 | 6.0 |
Protein Folding | 3 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Crohn Disease/*immunology | 2 | 5.0 |
Membrane Proteins/*immunology | 2 | 3.0 |
Cathepsins/immunology | 2 | 33.0 |
Sex Factors | 2 | 0.0 |
Conserved Sequence/genetics | 2 | 1.0 |
Inflammation | 2 | 0.0 |
Phagocytosis | 8 | 2.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Bipolar Disorder/classification/*genetics | 2 | 100.0 |
National Institute of Mental Health (U.S.) | 2 | 40.0 |
Pedigree | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Immunoglobulin A/blood | 2 | 1.0 |
Recurrence | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Blood Proteins/*chemistry/metabolism | 2 | 33.0 |
Antibodies, Antineutrophil Cytoplasmic/*analysis | 2 | 20.0 |
Blood Proteins/*isolation & purification | 2 | 12.0 |
DNA Primers/chemistry | 2 | 0.0 |
Lipopolysaccharides/*immunology | 2 | 2.0 |
Blotting, Northern | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Protein Conformation | 3 | 0.0 |
In Vitro | 12 | 0.0 |
Antibodies, Antineutrophil Cytoplasmic | 5 | 12.0 |
*Carrier Proteins | 2 | 0.0 |
Lipid A/metabolism | 3 | 33.0 |
Flow Cytometry | 4 | 0.0 |
Recombinant Proteins/pharmacology/therapeutic use | 2 | 5.0 |
Biological Markers/blood | 2 | 0.0 |
Gram-Negative Bacteria/immunology | 2 | 15.0 |
Salmonella typhimurium/immunology | 2 | 25.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
*Escherichia coli | 2 | 5.0 |
Monocytes/*metabolism | 2 | 0.0 |
Lipopolysaccharides/chemistry | 2 | 28.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Blood Proteins/*therapeutic use | 5 | 100.0 |
Blood Proteins/*physiology | 3 | 12.0 |
Limulus Test | 5 | 21.0 |
Acute-Phase Proteins/*analysis | 2 | 2.0 |
Antigens, CD14 | 4 | 1.0 |
Survival Rate | 3 | 0.0 |
Anti-Infective Agents/*therapeutic use | 2 | 8.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Neutrophils/chemistry | 3 | 21.0 |
Lipopolysaccharides/toxicity | 2 | 2.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 2 | 1.0 |
Neutrophils/*physiology | 5 | 3.0 |
*Neutrophils | 2 | 13.0 |
Permeability | 7 | 4.0 |
Papio | 2 | 1.0 |
Blood Pressure/physiology | 2 | 1.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Lipopolysaccharides | 2 | 1.0 |
Swine | 3 | 0.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 3 | 0.0 |
Cell Membrane Permeability | 3 | 1.0 |
Carrier Proteins/immunology | 2 | 5.0 |
Neutrophils/*chemistry | 3 | 25.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Blood Proteins/metabolism/*pharmacology | 3 | 60.0 |
Diagnosis, Differential | 2 | 0.0 |
*Evolution, Molecular | 2 | 0.0 |
Multigene Family/*genetics | 2 | 1.0 |
Gram-Negative Bacterial Infections/*immunology | 2 | 28.0 |
Molecular Weight | 5 | 0.0 |
Endotoxins/*antagonists & inhibitors | 2 | 16.0 |
Kinetics | 3 | 0.0 |
Angiotensinogen/*genetics | 2 | 2.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Autoantibodies/immunology | 2 | 1.0 |
Sequence Analysis, DNA | 2 | 0.0 |
